HIV medication can be used safely with gender-affirming hormone therapy
New research shows HIV medications can be taken at the same time as hormone treatment without losing potency of either therapy.
2024-03-04
(Press-News.org) New research definitively shows that HIV antiretrovirals can be taken together with gender-affirming hormone therapy without changing how well either drug works. The study findings can help healthcare providers address potential patient concerns that one drug will counteract the other.
“This study is the first head-to-head pharmacokinetic analysis of two common HIV medications and long-term feminizing hormone therapy use,” says Walter Kraft, MD, director of the Division of Clinical Pharmacology at the Sidney Kimmel Medical College at Thomas Jefferson University. “This research should help doctors reassure patients that it’s safe and important to continue HIV medications alongside their hormone regimen.” The study was published in the journal, Clinical and Translational Science.
Transgender women are at a 50 times greater risk of HIV infection than the general public, and stopping HIV medication can have long-term consequences, including disease progression to AIDS.
The study enrolled eight transgender women who were taking gender-affirming hormone therapy and who were HIV negative. As part of the cross-over study, half of the women were asked to take one of three treatments - one after the other: first HIV therapy, then hormone therapy and then finally, a combination of the two. There was a 14-day “wash-out” period between each therapy when participants took no therapy. The researchers took blood and urine samples regularly to test for drug and hormone concentrations during and after treatment.
To ensure the order of treatments didn’t affect the result, the other half of the women in the study had the treatment in the opposite order, starting with the combination hormone plus HIV therapy, followed by hormone therapy alone, and then HIV medication alone.
Although the number of patients wasn’t large, the amount of data collected on each participant was comprehensive. In addition, the use of a cross-over study design – where each participant takes each of the therapy combinations and essentially serves as her own control – provided enough statistical power to confirm the scientific validity of the findings. The duration and intensity also speaks to the personal sacrifice that each participant made in order to take part in the study.
“We asked women who were HIV negative to participate because it wouldn’t be ethical to ask those who are HIV positive to stop taking HIV medication,” says Dr. Kraft. “We realized that it was a big ask for transgender women to halt their gender-affirming hormone therapy for the sake of science. The ones who did, understood how valuable this information could be for their community. It’s part of why this study is so important.”
The study revealed that it is safe for patients to use HIV antiretrovirals medications together with gender-affirming hormone medications without losing potency of either drug. In fact, estrogen and testosterone levels were basically unchanged when participants also took HIV medications. “The hormone concentration in the blood was close enough that you wouldn’t have to change hormone dosing at all,” said first author Kevin Lam, PharmD.
“This study is so important for the trans community,” says Dr. Lam. “There’s a big risk with scaling back or stopping HIV medication. The virus can develop resistance to the medications, making them ineffective at keeping the virus in check.”
“We hope that this study will help reassure the trans community living with HIV that it’s safe and crucial to continue taking their antiretrovirals to control HIV infection.”
###
This study was conceived, written and conducted by Thomas Jefferson University employees. Funding was supported by an Investigator Studies Program grant provided by Merck & Co., Inc. [MISP59198]. K.L. and E.L. were supported by the National Institutes of Health institutional training grant [T32GM008562].
Article reference: Kevin Lam, Walter K. Kraft, Tingting Zhan, Edwin Lam, “Bidirectional Pharmacokinetics of doravirine, tenofovir, and feminizing hormones in transgender women (IDentify): a randomized crossover trial,” Clinical and Translational Science, DOI: DOI:10.1111/cts.13721 , 2024.
Media Contact: Edyta Zielinska, 267-234-3553, edyta.zielinska@jefferson.edu
END
ELSE PRESS RELEASES FROM THIS DATE:
2024-03-04
Cervical cancer is among the most common malignancies affecting women worldwide. In 2020 alone, approximately 600,000 women were diagnosed with this disease, and over 314,000 died from it. In 99% of the cases, cervical cancer cells harbor human papilloma virus (HPV), and thus, HPV vaccines are an effective way to mitigate the risk of developing this disease. Unfortunately, such preventive measures are useless against established cancers, which are generally incurable once they become metastatic or relapsing.
Fortunately, scientists have made substantial progress in developing a promising ...
2024-03-04
A new analysis of freshwater resources across the globe shows that human activity has pushed variation in the planet’s freshwater cycle well outside of its pre-industrial range. The study shows that the updated planetary boundary for freshwater change was surpassed by the mid-twentieth century. In other words, for the past century, humans have been pushing the Earth’s freshwater system far beyond the stable conditions that prevailed before industrialization.
This is the first time that global water cycle change has been assessed over such a long timescale with an appropriate reference baseline. The findings, published in Nature Water, show that human ...
2024-03-04
CAMBRIDGE, MA -- When listening to music, the human brain appears to be biased toward hearing and producing rhythms composed of simple integer ratios — for example, a series of four beats separated by equal time intervals (forming a 1:1:1 ratio).
However, the favored ratios can vary greatly between different societies, according to a large-scale study led by researchers at MIT and the Max Planck Institute for Empirical Aesthetics and carried out in 15 countries. The study included 39 groups of participants, many of whom came from societies ...
2024-03-04
WINSTON-SALEM, N.C. – March 4, 2024 – Parkinson’s disease is a neurological disorder that affects movement and muscle control. One characteristic of the disease is the deficiency of dopamine, a neurotransmitter or brain chemical that plays a role in movement and can impact how people think and feel.
Dopaminergic medicines can help alleviate the symptoms of Parkinson’s disease. However, in some patients, the medications can cause impulse control disorder (ICD), characterized by risky behavior such as excessive gambling, shopping, ...
2024-03-04
There are stark differences between European countries when it comes to both the reimbursement of, and access to, new treatments for patients with early-stage lung cancer. There are also differences in reimbursement times and indications between the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Researchers from Amsterdam UMC Cancer Center Amsterdam analysed the landscape, and their results are published today in The Lancet Regional Health Europe as part of a series on the latest developments in the treatment of this lung cancer.
"Tackling inequalities in access to care must be a common European priority," ...
2024-03-04
Problems with iron levels in the blood and the body’s ability to regulate this important nutrient as a result of SARS-CoV-2 infection could be a key trigger for long COVID, new research has discovered.
The discovery not only points to possible ways to prevent or treat the condition, but could help explain why symptoms similar to those of long COVID are also commonly seen in a number of post-viral conditions and chronic inflammation.
Although estimates are highly variable, as many as three in 10 people infected with SARS-CoV-2 could go on to develop long COVID, with symptoms including fatigue, ...
2024-03-04
Regularly substituting meat for mycoprotein such as Quorn could help to lower bad cholesterol by 10-percent, which is comparable to switching to a Mediterranean or vegan diet.
New research by the University of Exeter, published in Clinical Nutrition, also found substituting meat for Quorn reduces blood glucose and c-peptide concentrations associated with diabetes, cardiovascular disease and all-cause mortality.
With one in six UK adults suffering from raised cholesterol, the findings indicate that mycoprotein - the high protein, high-fibre food source that’s the main ingredient in Quorn - could play a key role in ...
2024-03-04
We need to stop designing new AI technology just because we can, causing people to adapt practices, habits and laws to fit the new technology; instead we need to design AI that fits exactly with what we need, according to human-centred AI advocates.
Fifty experts from around the world have contributed research papers to a new book on how to make AI more ‘human-centred,’ exploring the risks — and missed opportunities — of not using this approach and practical ways to implement it.
The experts come from over 12 countries, including Canada, France, Italy, Japan, New Zealand and the UK, and more ...
2024-03-04
An important discovery from the NCI-MATCH precision medicine initiative is being published today in Clinical Cancer Research, a journal of the American Association for Cancer Research. Trastuzumab-pertuzumab, a drug combination approved by the US Food and Drug Administration (FDA) to treat patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, shrunk tumors in patients with several other types of cancer with high levels of the HER2 gene. NCI-MATCH (Molecular Analysis for Therapy Choice) is one of the first ...
2024-03-04
Obesity is a risk factor for stillbirth, and the risk increases as pregnancy advances to term, according to a large study published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.221450.
The overall risk of stillbirth in pregnancy is approximately 0.4% in Canada. "Our findings suggest that an earlier delivery date may help reduce the risk of stillbirth for pregnant people with obesity," says lead author Dr. Naila Ramji, a high-risk pregnancy specialist in Fredericton, New Brunswick, and ...
LAST 30 PRESS RELEASES:
[Press-News.org] HIV medication can be used safely with gender-affirming hormone therapy
New research shows HIV medications can be taken at the same time as hormone treatment without losing potency of either therapy.
